Uso de magnesio intravenoso en la exacerbación de la enfermedad pulmonar obstructiva crónica severa: ¿realmente es útil?
Contenido principal del artículo
Keywords
Enfermedad Pulmonar Obstructiva Crónica, Recurrencia, Brote de los Síntomas, Sulfato de Magnesio
Resumen
La Enfermedad Pulmonar Obstructiva Crónica (EPOC), tercera causa global de muerte, afecta principalmente a individuos menores de 70 años en países de bajos y medianos ingresos. Las estrategias para su manejo incluyen cese del tabaquismo, vacunación contra la influenza y broncodilatadores. Se investiga el papel del magnesio sérico en las exacerbaciones de EPOC severa, sugiriendo que el sulfato de magnesio como adyuvante podría reducir hospitalizaciones, duración de estancia y síntomas respiratorios. Aunque la evidencia es limitada y heterogénea, apunta hacia un impacto positivo en el volumen espiratorio forzado. Se requieren más estudios para clarificar su eficacia específica en casos severos de EPOC.
Citas
1. World Health Organization. Chronic obstructive pulmonary disease (COPD) [Internet]. [Consulted 25 Mar 2023]. Available in: https://www.who.int/es/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)
2. Safiri S, Carson-Chahhoud K, Noori M, Nejadghaderi SA, Sullman MJM, Ahmadian Heris J, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. BMJ. 2022; 378:e069679.
3. Feizi H, Alizadeh M, Nejadghaderi SA, Noori M, Sullman MJM, Ahmadian Heris J, et al. The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990-2019. Respir Res. 2022; 23(1):319.
4. Perez-Padilla R, Menezes AMB. Chronic Obstructive Pulmonary Disease in Latin America. Ann Glob Health. 2019; 85(1):7.
5. Olortegui-Rodriguez JJ, Soriano-Moreno DR, Benites-Bullón A, Pelayo-Luis PP, Huaringa-Marcelo J. Prevalence and incidence of chronic obstructive pulmonary disease in Latin America and the Caribbean: a systematic review and meta-analysis. BMC Pulm Med. 2022; 22:273.
6. MacLeod M, Papi A, Contoli M, Beghé B, Celli BR, Wedzicha JA, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology. 2021; 26(6):532-551.
7. Kshirsagar K, Patil VC. Chronic obstructive pulmonary disease: Is serum magnesium level a risk factor for its acute exacerbation? Caspian J Intern Med. 2021; 12(2):223-227.
8. Jahangir A, Zia Z, Khan Niazi MR, Sahra S, Jahangir A, Sharif MA, et al. Efficacy of magnesium sulfate in the chronic obstructive pulmonary disease population: A systematic review and meta-analysis. Adv Respir Med. 2022; 90:125–133.
9. Ni H, Aye SZ, Naing C. Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2022; 5(5):CD013506.
10. Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012; 7:757-64.
11. Mathioudakis AG, Janssens W, Sivapalan P, Singanayagam A, Dransfield MT, Jensen JS, et al. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020; 75(6):520-527.
12. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007; 370(9589):786-96.
13. Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med. 2014; 35(1):157-63.
14. Huot-Marchand S, Nascimento M, Culerier E, Bourenane M, Savigny F, Panek C, et al. Cigarette smoke-induced gasdermin D activation in bronchoalveolar macrophages and bronchial epithelial cells dependently on NLRP3. Front Immunol. 2022; 13:918507.
15. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184:662–71.
16. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006; 173(10):1114-21.
17. Matsunaga K, Harada M, Suizu J, Oishi K, Asami-Noyama M, Hirano T. Comorbid Conditions in Chronic Obstructive Pulmonary Disease: Potential Therapeutic Targets for Unmet Needs. J Clin Med. 2020; 9(10):3078.
18. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care. 2003; 48(12):1204-13.
19. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal. 2007; 29:1224-1238.
20. Franssen FM, Alter P, Bar N, Benedikter BJ, Iurato S, Maier D, et al. Personalized medicine for patients with COPD: where are we? Int J Chron Obstruct Pulmon Dis. 2019; 14:1465-1484.
21. Celli BR, Wedzicha JA. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med. 2019; 381(13):1257-1266.
22. Anzueto A, Miravitlles M. Chronic Obstructive Pulmonary Disease Exacerbations: A Need for Action. Am J Med. 2018; 131(9S):15-22.
23. Rosell A, Monsó E, Soler N, Torres F, Angrill J, Riise G, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005; 165(8):891-7.
24. Kim VL, Coombs NA, Staples KJ, Ostridge KK, Williams NP, Wootton SA, et al. Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. Eur Respir J. 2017; 50(4):1700853.
25. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2023 report [Internet]. [Consultado 05 Mar 2023]. Disponible en: https://goldcopd.org/2023-gold-report-2/
26. Mathew AA, Panonnummal R. 'Magnesium'-the master cation-as a drug-possibilities and evidences. Biometals. 2021; 34(5):955-986.
27. Gottlieb M, Moyer E, Meissner H. What Is the Role of Magnesium Sulfate for Acute Exacerbations of Chronic Obstructive Pulmonary Disease? Ann Emerg Med. 2022; S0196-0644(22)00577-7.
28. Makwana S, Patel A, Sonagara M. Correlation Between Serum Magnesium Level and Acute Exacerbation in Patients With Chronic Obstructive Pulmonary Disease (COPD). Cureus. 2022; 14(6):e26229.
29. Abreu González J, Hernández García C, Abreu González P, Martín García C, Jiménez A. Efecto del sulfato de magnesio intravenoso en la exacerbación de la EPOC que precisa hospitalización: estudio aleatorizado controlado con placebo. Arch Bronconeumol. 2006; 42(8):384-7.
30. Edwards L, Shirtcliffe P, Wadsworth K, Healy B, Jefferies S, Weatherall M, et al. Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax. 2013; 68(4):338-43.
31. Nouira S, Bouida W, Grissa MH, Beltaief K, Trimech MN, Boubaker H, et al. Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomized trial. Am J Ther. 2014; 21(3):152-8.
32. Mukerji S, Shahpuri B, Clayton-Smith B, Smith N, Armstrong P, Hardy M, et al. Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. N Z Med J. 2015; 128(1425):34-42.
33. Jahanian F, Khatir IG, Ahidashti HA, Amirifard S. The Effect of Intravenous Magnesium Sulphate as an Adjuvant in the Treatment of Acute Exacerbations of COPD in the Emergency Department: A Double-Blind Randomized Clinical Trial. Ethiop J Health Sci. 2021; 31(2):267-274.
34. Jahangir A, Zia Z, Niazi MRK, Sahra S, Jahangir A, Sharif MA, et al. Efficacy of magnesium sulfate in the chronic obstructive pulmonary disease population: a systematic review and meta-analysis. Adv Respir Med. 2022. Online ahead of print
35. Zanforlini BM, Ceolin C, Trevisan C, Alessi A, Seccia DM, Noale M, et al. Clinical trial on the effects of oral magnesium supplementation in stable-phase COPD patients. Aging Clin Exp Res. 2022; 34(1):167-174.
36. Mamary AJ, Stewart JI, Kinney GL, Hokanson JE, Shenoy K, Dransfield MT, et al. Race and Gender Disparities are Evident in COPD Underdiagnoses Across all Severities of Measured Airflow Obstruction. Chronic Obstr Pulm Dis. 2018; 5(3):177-184.
37. Gilkes A, Ashworth M, Schofield P, Harries TH, Durbaba S, Weston C, et al. Does COPD risk vary by ethnicity? A retrospective cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2016; 11:739-46.
38. Eisner MD, Blanc PD, Omachi TA, Yelin EH, Sidney S, Katz PP, et al. Socioeconomic status, race and COPD health outcomes. J Epidemiol Community Health. 2011; 65(1):26-34.
39. Lozada-Martinez ID, Suarez-Causado A, Solana-Tinoco JB. Ethnicity, genetic variants, risk factors and cholelithiasis: The need for eco-epidemiological studies and genomic analysis in Latin American surgery. Int J Surg. 2022; 99:106589.
40. Lozada-Martinez ID, Bolaño-Romero MP, Picón-Jaimes YA, Moscote-Salazar LR, Narvaez-Rojas AR. Quality or quantity? Questions on the growth of global scientific production. Int J Surg. 2022; 105:106862.
2. Safiri S, Carson-Chahhoud K, Noori M, Nejadghaderi SA, Sullman MJM, Ahmadian Heris J, et al. Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. BMJ. 2022; 378:e069679.
3. Feizi H, Alizadeh M, Nejadghaderi SA, Noori M, Sullman MJM, Ahmadian Heris J, et al. The burden of chronic obstructive pulmonary disease and its attributable risk factors in the Middle East and North Africa region, 1990-2019. Respir Res. 2022; 23(1):319.
4. Perez-Padilla R, Menezes AMB. Chronic Obstructive Pulmonary Disease in Latin America. Ann Glob Health. 2019; 85(1):7.
5. Olortegui-Rodriguez JJ, Soriano-Moreno DR, Benites-Bullón A, Pelayo-Luis PP, Huaringa-Marcelo J. Prevalence and incidence of chronic obstructive pulmonary disease in Latin America and the Caribbean: a systematic review and meta-analysis. BMC Pulm Med. 2022; 22:273.
6. MacLeod M, Papi A, Contoli M, Beghé B, Celli BR, Wedzicha JA, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology. 2021; 26(6):532-551.
7. Kshirsagar K, Patil VC. Chronic obstructive pulmonary disease: Is serum magnesium level a risk factor for its acute exacerbation? Caspian J Intern Med. 2021; 12(2):223-227.
8. Jahangir A, Zia Z, Khan Niazi MR, Sahra S, Jahangir A, Sharif MA, et al. Efficacy of magnesium sulfate in the chronic obstructive pulmonary disease population: A systematic review and meta-analysis. Adv Respir Med. 2022; 90:125–133.
9. Ni H, Aye SZ, Naing C. Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2022; 5(5):CD013506.
10. Pasquale MK, Sun SX, Song F, Hartnett HJ, Stemkowski SA. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2012; 7:757-64.
11. Mathioudakis AG, Janssens W, Sivapalan P, Singanayagam A, Dransfield MT, Jensen JS, et al. Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020; 75(6):520-527.
12. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007; 370(9589):786-96.
13. Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med. 2014; 35(1):157-63.
14. Huot-Marchand S, Nascimento M, Culerier E, Bourenane M, Savigny F, Panek C, et al. Cigarette smoke-induced gasdermin D activation in bronchoalveolar macrophages and bronchial epithelial cells dependently on NLRP3. Front Immunol. 2022; 13:918507.
15. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184:662–71.
16. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006; 173(10):1114-21.
17. Matsunaga K, Harada M, Suizu J, Oishi K, Asami-Noyama M, Hirano T. Comorbid Conditions in Chronic Obstructive Pulmonary Disease: Potential Therapeutic Targets for Unmet Needs. J Clin Med. 2020; 9(10):3078.
18. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care. 2003; 48(12):1204-13.
19. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. European Respiratory Journal. 2007; 29:1224-1238.
20. Franssen FM, Alter P, Bar N, Benedikter BJ, Iurato S, Maier D, et al. Personalized medicine for patients with COPD: where are we? Int J Chron Obstruct Pulmon Dis. 2019; 14:1465-1484.
21. Celli BR, Wedzicha JA. Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. N Engl J Med. 2019; 381(13):1257-1266.
22. Anzueto A, Miravitlles M. Chronic Obstructive Pulmonary Disease Exacerbations: A Need for Action. Am J Med. 2018; 131(9S):15-22.
23. Rosell A, Monsó E, Soler N, Torres F, Angrill J, Riise G, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med. 2005; 165(8):891-7.
24. Kim VL, Coombs NA, Staples KJ, Ostridge KK, Williams NP, Wootton SA, et al. Impact and associations of eosinophilic inflammation in COPD: analysis of the AERIS cohort. Eur Respir J. 2017; 50(4):1700853.
25. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2023 report [Internet]. [Consultado 05 Mar 2023]. Disponible en: https://goldcopd.org/2023-gold-report-2/
26. Mathew AA, Panonnummal R. 'Magnesium'-the master cation-as a drug-possibilities and evidences. Biometals. 2021; 34(5):955-986.
27. Gottlieb M, Moyer E, Meissner H. What Is the Role of Magnesium Sulfate for Acute Exacerbations of Chronic Obstructive Pulmonary Disease? Ann Emerg Med. 2022; S0196-0644(22)00577-7.
28. Makwana S, Patel A, Sonagara M. Correlation Between Serum Magnesium Level and Acute Exacerbation in Patients With Chronic Obstructive Pulmonary Disease (COPD). Cureus. 2022; 14(6):e26229.
29. Abreu González J, Hernández García C, Abreu González P, Martín García C, Jiménez A. Efecto del sulfato de magnesio intravenoso en la exacerbación de la EPOC que precisa hospitalización: estudio aleatorizado controlado con placebo. Arch Bronconeumol. 2006; 42(8):384-7.
30. Edwards L, Shirtcliffe P, Wadsworth K, Healy B, Jefferies S, Weatherall M, et al. Use of nebulised magnesium sulphate as an adjuvant in the treatment of acute exacerbations of COPD in adults: a randomised double-blind placebo-controlled trial. Thorax. 2013; 68(4):338-43.
31. Nouira S, Bouida W, Grissa MH, Beltaief K, Trimech MN, Boubaker H, et al. Magnesium sulfate versus ipratropium bromide in chronic obstructive pulmonary disease exacerbation: a randomized trial. Am J Ther. 2014; 21(3):152-8.
32. Mukerji S, Shahpuri B, Clayton-Smith B, Smith N, Armstrong P, Hardy M, et al. Intravenous magnesium sulphate as an adjuvant therapy in acute exacerbations of chronic obstructive pulmonary disease: a single centre, randomised, double-blinded, parallel group, placebo-controlled trial: a pilot study. N Z Med J. 2015; 128(1425):34-42.
33. Jahanian F, Khatir IG, Ahidashti HA, Amirifard S. The Effect of Intravenous Magnesium Sulphate as an Adjuvant in the Treatment of Acute Exacerbations of COPD in the Emergency Department: A Double-Blind Randomized Clinical Trial. Ethiop J Health Sci. 2021; 31(2):267-274.
34. Jahangir A, Zia Z, Niazi MRK, Sahra S, Jahangir A, Sharif MA, et al. Efficacy of magnesium sulfate in the chronic obstructive pulmonary disease population: a systematic review and meta-analysis. Adv Respir Med. 2022. Online ahead of print
35. Zanforlini BM, Ceolin C, Trevisan C, Alessi A, Seccia DM, Noale M, et al. Clinical trial on the effects of oral magnesium supplementation in stable-phase COPD patients. Aging Clin Exp Res. 2022; 34(1):167-174.
36. Mamary AJ, Stewart JI, Kinney GL, Hokanson JE, Shenoy K, Dransfield MT, et al. Race and Gender Disparities are Evident in COPD Underdiagnoses Across all Severities of Measured Airflow Obstruction. Chronic Obstr Pulm Dis. 2018; 5(3):177-184.
37. Gilkes A, Ashworth M, Schofield P, Harries TH, Durbaba S, Weston C, et al. Does COPD risk vary by ethnicity? A retrospective cross-sectional study. Int J Chron Obstruct Pulmon Dis. 2016; 11:739-46.
38. Eisner MD, Blanc PD, Omachi TA, Yelin EH, Sidney S, Katz PP, et al. Socioeconomic status, race and COPD health outcomes. J Epidemiol Community Health. 2011; 65(1):26-34.
39. Lozada-Martinez ID, Suarez-Causado A, Solana-Tinoco JB. Ethnicity, genetic variants, risk factors and cholelithiasis: The need for eco-epidemiological studies and genomic analysis in Latin American surgery. Int J Surg. 2022; 99:106589.
40. Lozada-Martinez ID, Bolaño-Romero MP, Picón-Jaimes YA, Moscote-Salazar LR, Narvaez-Rojas AR. Quality or quantity? Questions on the growth of global scientific production. Int J Surg. 2022; 105:106862.
Barra lateral del artículo
Publicado
feb 12, 2024
Detalles del artículo
Cómo citar
Brett-Cano, P. J., Jaramillo-Acosta, M. A., Jaramillo-Mejía, E. A., García-Jiménez, L. M., Romero-Gómez, M. Ángel, Arboleda-Núñez, J. V., Delgado-Marrugo, R. D., & Picón-Jaimes, Y. A. (2024). Uso de magnesio intravenoso en la exacerbación de la enfermedad pulmonar obstructiva crónica severa: ¿realmente es útil? . Revista Hispanoamericana De Ciencias De La Salud, 9(3), 214–222. https://doi.org/10.56239/rhcs.2023.93.675
Sección
Artículos de Revisión
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
La RHCS usa la licencia Creative Commons 4.0 Internacional (CC BY 4.0). Para obtener más información, visite https://creativecommons.org/licenses/by/4.0/